The success of pediatric solid organ transplantation has been largely due to advancements in surgical techniques, technology, and preoperative and postoperative care. Potent immunosuppression continues to reduce the incidence and severity of rejection, and improve long-term survival. However, there is growing awareness of the role immunosuppression plays in contributing to the incidence of cytomegalovirus, Epstein-Barr virus, and Epstein-Barr virus–associated posttransplant lymphoproliferative disease. Herpes viruses such as these present as primary or recurrent disease and continue to be a significant source of morbidity and mortality in transplant recipients. This paper reviews the predictors of disease, clinical features, diagnosis, and methods of treatment of these major posttransplant viral syndromes. As part of the human herpes virus family, varicella-zoster virus will also be discussed. A case study shows the delicate balance of treating concomitant varicella infection at the time of transplantation.
Get full access to this article
View all access options for this article.
References
1.
MazariegosGVReyesJ. An update of current clinical practices in pediatric organ transplantation. Pediatr Rev.1999;20:363–375.
2.
SchowengerdtKONaftelDCSeibPM. Infection after pediatric heart transplant: Results of a multi-institutional study. J Heart Lung Transplant.1997;16:1207–1216.
3.
MartinS. Posttransplant lymphoproliferative disease in a pediatric multivisceral transplant recipient. Crit Care Nurse. June 1998;18:74–80.
4.
BreinigMKZitelliBStarzlTEHoM. Epstein-Barr virus, cytomegalovirus and other viral infections in children after transplant. J Infect Dis.1999;156:273–279.
5.
BoyleGJMichaelsMGWebberSA. Posttransplantation lymphoproliferative disorders in pediatric thoracic organ recipients. J Pediatr.1997;131:309–313.
McDermidSWJordanSLeeGS. Prevention and preemptive therapy of posttransplant lymphoproliferative disease in pediatric liver recipients. Transplantation.1998;66:1604–1611.
8.
SwinnenLJCostanzo-NordinMKFisherSG. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac transplant recipients. N Engl J Med.1990;323:1723–1728.
9.
ArmitageJMFrickerFJDel NidoP. A decade (1982–1992) of pediatric cardiac transplantation and the impact of FK506 immunosuppression. J Thorac Cardiovasc Surg.1993;105:464–472.
10.
DeschlerDGOsorioRAscherNLLeeKC. Posttransplantation lymphoproliferative disorder in patients under primary tacrolimus (FK506) immunosuppression [review]. Arch Otolaryngol Head Neck Surg.1995;121:1037–1041.
11.
TenneyFSakarcanA. Fatal cytomegalovirus disease in a high-risk renal transplant recipient. Pediatr Nephrol. January 2001;16:8–10.
12.
FishmanJARubinRH. Infection in organ transplant recipients. N Engl J Med.1998;338:1741–1751.
13.
RubinR. Infection in organ transplant recipients. In: RubinRHYoungLS, eds. Clinical Approach to Infection in the Compromised Host.3rd ed.New York, NY: Plenum Medical Book Company; 1994:629–705.
14.
KoskinenPKNieminenMSKrogerusLA. Cytomegalovirus infection and accelerated cardiac allograft vasculopathy in human cardiac allografts. J Heart Lung Transplant.1993;12:724–729.
15.
HalwachsGZachRPogglitschH. A rapid *immunocyto-chemical assay for CMV detection in peripheral blood of organ-transplant patients in clinical practice. Transplantation.1993;56:338–342.
16.
SchowengerdtKONiJDenfieldSW. Diagnosis, surveillance, and epidemiologic evaluation of viral infections in pediatric cardiac transplant recipients with the use of polymerase chain reaction. J Heart Lung Transplant.1996;15:111–123.
17.
PatelRSnydmanDRRubinRH. Cytomegalovirus prophylaxis in solid organ transplant recipients. Transplantation.1996;61:1279–1289.
18.
America Academy of Pediatrics.The Red Book.24th ed.Elk Grove, Ill: American Academy of Pediatrics; 1997.
19.
WebberSA. Post-transplant lymphoproliferative disorders: A preventable complication of solid organ transplantation? Pediatr Transplant. May1999;3:95–99.
20.
RiddlerSABreinigMCMcKnightJLC. Increased levels of circulating Epstein-Barr Virus (EBV)-infected lymphocytes and decreased EBV nuclear antigen antibody responses are associated with the development of posttransplant lymphoproliferative disease in solid-organ transplant recipients. Blood.1994;84:972–984.
21.
KenagyDNSchlesingerYWeckK. Epstein-Barr virus in DNA in peripheral blood leukocytes of patients with posttransplant lymphoproliferative disease. Transplantation.1995;60:547–554.
22.
RoweDTQuLReyesJ. Use of quantitative competitive PCR to measure Epstein-Barr virus genome load in the peripheral blood of pediatric transplant patients with lymphoproliferative disorders. J Clin Microbiol.1997;35:1612–1615.
23.
GreenMMichaelsMGWebberSARoweDReyesJ. The management of Epstein-Barr virus associated post-transplant lymphoproliferative disorders in pediatric solid-organ transplant recipients. Pediatr Transplant.1999;3:271–281.
24.
BabcockGJDeckerLLFreemanRB. Epstein-Barr virus-infected resting memory B cells, not proliferating lymphoblasts, accumulate in the peripheral blood of immunosuppressed patients. J Exp Med.1999;190:567–576.
25.
GreenMCacciarelliTVMazariegosGV. Serial measurement of Epstein-Barr viral load in peripheral blood in pediatric liver transplant recipients during treatment for *posttransplant lymphoproliferative disease. Transplantation.1998;66:1641–1644.
26.
DrorYGreenbergMTaylorG. Lymphoproliferative disorders after organ transplantation in children. Transplantation.1999;67:990–998.
HarrisNLFerryJASwerdlowSH. Posttransplant lymphoproliferative disorders: Summary of Society for Hematopathology Workshop. Semin Diagn Pathol. February 1997;14:8–14.
29.
MurrayJEWilsonRETilneyNL. Five years experience in renal transplantation with immunosuppressive drugs: Survival, function, complications and the role of lymphocyte depletion by thoracic duct fistula. Ann Surg.1968;167:416–435.
30.
KocoshisSA. Endoscopic diagnosis of lymphoproliferative disease after solid organ transplantation. J Pediatr Gastroenterol.1998;28:375–376.
31.
Mamzer-BruneelMFMorelonEBourquelotPKreisHHermineO. Post-transplant lymphoproliferative disease: Treatment and prognosis. Hématologie.1998;4:431–439.
32.
CraigFEGulleyMLBanksPM. Posttransplantation lymphoproliferative disorders. Am J Clin Pathol.1993;99:265–276.
33.
MorrisonVADunnDLManivelJCGajl-PeczalskaKJPetersonBA. Clinical characteristics of post-transplant lymphoproliferative disorders. Am J Med. July 1994;97:14–24.
34.
SwinnenLJ. Treatment of organ transplant-related lymphoma. Hematol Oncol Clin North Am.1997;11:963–973.
35.
JainAKReyesJMazariegosG. Comparison of posttransplant lymphoproliferative disorders (PTLD) in children under cyclosporine and tacrolimus, 766 consecutive recipients: 15 years experience. Pediatr Transplant.2000;4(suppl 2):150–151.
36.
CoxKLLawrence-MiyasakiLSGarcia-KennedyR. An increased incidence of Epstein-Barr virus infection and lymphoproliferative disorder in young children on FK506 after liver transplantation. Transplantation.1995;59:524–529.
37.
PoseyLAKerschnerJEConleySF. Posttransplantation lymphoproliferative disease in children: Otolaryngologic manifestations and management. South Med J.1999;92:1079–1082.
38.
Grillo-LopezAJWhiteCAVarnsC. Overview of the clinical development of Rituximab: First monoclonal antibody approved for the treatment of lymphoma. Semin Onc. October 1999;26(5suppl 14):66–73.
39.
MilpiedNVasseurBParquetN. Humanized anti-CD 20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: A retrospective analysis of 32 patients. Ann Oncol.2000;11(suppl 1):113–116.
40.
BroyerMTeteMJGuestGGagnadouxMFRouziouxC. Varicella and zoster in children after kidney transplantation: Long-term results of vaccination. Pediatrics. January 1997;99:35–39.
41.
McGregorRSZitelliBJUrbachAHMalatackJJGartnerJC. Varicella in pediatric orthotopic liver transplant patients. Pediatrics.1989;83:256–261.
42.
GershonAA. Immunizations for pediatric transplant patients. Kidney Int Suppl. October 1993;43(suppl):S87–S90.
43.
ZamoraISimonJMDaSilaMEPiquerasAI. Attenuated varicella virus vaccine in children with renal transplants. Pediatr Nephrol.1994;8:190–192.
44.
CohenMH. The unknown and the unknowable: Managing sustained uncertainty. West J Nurs Res. February 1993;15:77–95.
45.
CohenMH. The triggers of heightened parental uncertainty in chronic, life-threatening childhood illness. Qual Health Res. February 1995;5:63–77.
